Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Ipilimumab in Head and Neck Cancer
NCT02812524Phase 1Active, not recruiting
- Start
- Nov 2016
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab in squamous cell carcinoma of the head and neck (HNSCC). Primary endpoint: Number of surgeries delayed. Started Nov 2016; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02812524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812524.